Harmony Biosciences names Peter Anastasiou as its next CEO
Peter Anastasiou will lead Harmony Biosciences from Jan. 1, 2027, replacing Jeffrey Dayno, who will leave the company’s board on Dec. 31.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reports that Harmony Biosciences Holdings has appointed Chief Operating Officer Peter Anastasiou as president, chief executive and a board member. He will take over on Jan. 1, 2027.
Anastasiou will succeed Jeffrey M. Dayno, who is set to retire as president and CEO and leave the board on Dec. 31. Dayno will remain an independent adviser to the company throughout 2027, supporting its growth objectives.
Harmony also reaffirmed its full-year 2026 revenue guidance for Wakix at $1 billion to $1.04 billion. Wakix is a prescription medicine for excessive daytime sleepiness or cataplexy in people aged 6 and older who have narcolepsy.
why it matters
The leadership transition and unchanged revenue outlook give investors a reference point for assessing strategic continuity and the performance of Harmony’s key drug, Wakix.
instruments
sources
- Harmony Biosciences Appoints COO Peter Anastasiou as New CEO — Dow Jones Newswires, 12 October 2026 at 11:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗